Skip to main content
Premium Trial:

Request an Annual Quote

Genomenon Enters Chinese Market With Shanghai Shanyi Partnership

NEW YORK – Genomenon has entered the Chinese market by forming a partnership with Shanghai Shanyi Biological Technology Co., a provider of sequencing interpretation, variant validation, and other molecular technology services. 

Ann Arbor, Michigan-based Genomenon said today that the new partnership will allow the company to bring its Mastermind genomic search engine to clinical laboratories in China. 

"Our partnership with Shanghai Shanyi will allow us to expand our footprint in the China market, seamlessly integrating with their other best-of-breed end-to-end clinical [next-generation sequencing] solutions," Genomenon CEO Mike Klein said in a statement.

"We’re proud to bring Mastermind to clinical laboratories in China," added Lei Li, general manager of Shanghai Shanyi. Shanyi said that early work with Genomenon has helped customers reduce the amount of time they spend searching for variants of unknown significance by 60 percent to 80 percent.

Genomenon previously operated only in North America and Europe, through partnerships with the likes of US-based LifeMap Sciences, Parabricks, Belgian artificial intelligence vendor Diploid, and others. 

The company raised $2.5 million in private equity early this year.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.